Literature DB >> 15955868

Effects of quinine, quinidine, and chloroquine on alpha9alpha10 nicotinic cholinergic receptors.

Jimena A Ballestero1, Paola V Plazas, Sebastian Kracun, María E Gómez-Casati, Julián Taranda, Carla V Rothlin, Eleonora Katz, Neil S Millar, A Belén Elgoyhen.   

Abstract

In this study, we report the effects of the quinoline derivatives quinine, its optical isomer quinidine, and chloroquine on alpha9alpha10-containing nicotinic acetylcholine receptors (nAChRs). The compounds blocked acetylcholine (ACh)-evoked responses in alpha9alpha10-injected Xenopus laevis oocytes in a concentration-dependent manner, with a rank order of potency of chloroquine (IC50 = 0.39 microM) > quinine (IC50 = 0.97 microM) approximately quinidine (IC50= 1.37 microM). Moreover, chloroquine blocked ACh-evoked responses on rat cochlear inner hair cells with an IC50 value of 0.13 microM, which is within the same range as that observed for recombinant receptors. Block by chloroquine was purely competitive, whereas quinine inhibited ACh currents in a mixed competitive and noncompetitive manner. The competitive nature of the blockage produced by the three compounds was confirmed by equilibrium binding experiments using [3H]methyllycaconitine. Binding affinities (Ki values) were 2.3, 5.5, and 13.0 microM for chloroquine, quinine, and quinidine, respectively. Block by quinine was found to be only slightly voltage-dependent, thus precluding open-channel block as the main mechanism of interaction of quinine with alpha9alpha10 nAChRs. The present results add to the pharmacological characterization of alpha9alpha10-containing nicotinic receptors and indicate that the efferent olivocochlear system that innervates the cochlear hair cells is a target of these ototoxic antimalarial compounds.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15955868     DOI: 10.1124/mol.105.014431

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

Review 1.  New developments in understanding the mechanisms and function of spontaneous electrical activity in the developing mammalian auditory system.

Authors:  Helen J Kennedy
Journal:  J Assoc Res Otolaryngol       Date:  2012-04-17

Review 2.  The 5-HT3 receptor as a therapeutic target.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

Review 3.  The efferent medial olivocochlear-hair cell synapse.

Authors:  Ana Belén Elgoyhen; Eleonora Katz
Journal:  J Physiol Paris       Date:  2011-07-06

4.  Positive modulation of the α9α10 nicotinic cholinergic receptor by ascorbic acid.

Authors:  J C Boffi; C Wedemeyer; M Lipovsek; E Katz; D J Calvo; A B Elgoyhen
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

5.  Imprinted gene expression in fetal growth and development.

Authors:  L Lambertini; C J Marsit; P Sharma; M Maccani; Y Ma; J Hu; J Chen
Journal:  Placenta       Date:  2012-03-31       Impact factor: 3.481

6.  High diastereoselective amine-catalyzed Knoevenagel-Michael-cyclization-ring-opening cascade between aldehydes, 3-arylisoxazol-5(4H)-ones and 3-aminocyclohex-2-en-1-ones.

Authors:  Anatoly N Vereshchagin; Michail N Elinson; Yuliya E Anisina; Kirill A Karpenko; Alexander S Goloveshkin; Sergey G Zlotin; Mikhail P Egorov
Journal:  Mol Divers       Date:  2018-03-20       Impact factor: 2.943

7.  The antimalarial drugs quinine, chloroquine and mefloquine are antagonists at 5-HT3 receptors.

Authors:  A J Thompson; M Lochner; S C R Lummis
Journal:  Br J Pharmacol       Date:  2007-05-14       Impact factor: 8.739

8.  Optical coherence tomography findings of quinine poisoning.

Authors:  John Christoforidis; Robert Ricketts; Theodore Loizos; Susie Chang
Journal:  Clin Ophthalmol       Date:  2011-01-11

9.  Antimalarial drugs inhibit human 5-HT(3) and GABA(A) but not GABA(C) receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

Review 10.  Inhibitors of connexin and pannexin channels as potential therapeutics.

Authors:  Joost Willebrords; Michaël Maes; Sara Crespo Yanguas; Mathieu Vinken
Journal:  Pharmacol Ther       Date:  2017-07-15       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.